Richard is the founder and CEO of XenoGesis. His clear scientific rationale, business direction, vision and entrepreneurial approach have seen XenoGesis consistently expand and grow to become the UK’s largest independent DMPK provider.

Richard set up the business in 2011, when he spotted a gap and opportunity in the market. XenoGesis now works with over 200 companies and Universities across the globe and has provided experimental data, advice and PK predictions on seven compounds that are now in the clinic.

The business has grown from three to over 30 employees in over eight years. In 2018, Richard led the move into state-of-the-art laboratories and offices at BioCity’s Discovery Building to provide the platform for future growth.

Richard gained a first-class honours degree in chemistry with awards for the best performance in every year, followed by a medicinal chemistry PhD with a Wellcome Trust scholarship at the University of Leicester and two subsequent postdoctoral positions at the Welsh School of Pharmacy. In 1997, Richard joined Astra Charnwood within Discovery DMPK, and progressed to Group and Project Leader at AstraZeneca. During that time Richard gained and developed an in-depth knowledge of all aspects of in vitro and in vivo DMPK from hit identification to candidate drug nomination and beyond.

In 2014, Richard was invited to become a Fellow of the Royal Society of Chemistry. Richard has also authored and co-authored twenty-one publications to date.

Richard Weaver PhD FRSC

XenoGesis Founder and CEO

Talk to a scientist... if you’d like to get in touch with one our scientists, please click here!